請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24053
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 游若? | |
dc.contributor.author | Yi-Hua Lee | en |
dc.contributor.author | 李逸華 | zh_TW |
dc.date.accessioned | 2021-06-08T05:14:55Z | - |
dc.date.copyright | 2011-08-02 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-01 | |
dc.identifier.citation | 王姿以。2009。攝食菊醣改善人體腸胃道菌相並降低糞便萃取液對HT-29及Caco-2毒性之研究。國立臺灣大學食品科技所碩士學位論文。台北。台灣。
江淑靜。2010。益生菌寡醣發酵液抑制大腸癌細胞增生及其對人類結腸細胞株 Int-407 抗細胞毒性研究。國立臺灣大學食品科技所碩士學位論文。台北。台灣。 行政院衛生署。2011。99年國人主要死因統計。行政院衛生署。台北。台灣。 沈明來。2004。試驗設計學。九州圖書文物有限公司。台北,台灣。 唐菁吟。2004。篩選富含類黃酮蔬果探討其免疫調節及抗發炎作用。國立中興大學食品科學碩士學位論文。台中。台灣。 陳倩琪、彭宣融、廖麗玲。2007a。基因體研究對乳酸菌機能保健品之產業發展潛力。農業生技產業季刊。11:52-29。 陳慶源、黃崇真、邱雪惠、廖啟成。2007b。乳酸菌之保健功效與產品開發。農業生技產業季刊。11:60-68。 陳穗葶。2005。數株乳酸菌胞外多醣對雙叉桿菌生長之助生性研究。國立臺灣大學食品科技研究所碩士學位論文。台北。台灣。 廖啟成。1998。乳酸菌之分類及應用。食品工業。30:1-10。 劉曲婷。2010a。餵食 Lactobacillus casei O1 及其胞外多醣對 1,2-二甲基聯胺誘導F344 大鼠結腸癌前病變之影響。國立臺灣大學食品科技研究所博士學位論文。台北。台灣。 劉家余。2010b。薏仁麩皮萃取物乙酸乙酯區分層之抗發炎效果。國立臺灣大學食品科技研究所碩士學位論文。台北。台灣。 賴永裕。2000。乳酸菌的深度應用。食品資訊。178:49-52。 AOAC. 1987. “Official Methods of Analysis,” 14th Ed. Association of Official Analytical Chemists. USA: Washington, D. C. Arunachalam, K. D. Role of bifidobacteria in nutrition, medicine and technology. Nutr. Res. 1999, 19, 1559-1597. Audy, J. Labrie, S.; Roy, D.; LaPointe, G. Sugar source modulated exopolysaccharide biosynthesis in Bifidobacterium longum subsp. longum CRC 002. Microbiology 2010, 156, 653-664. Baricault, L.; Denariaz, G.; Houri, J. J.; Bouley, C.; Sapin, C.; Trugnan, G. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis 1995, 16, 245-252. Braeqqer, C. P.; Nicholls, S.; Murch, S. H.; Stephens, S.; MacDonald, T. T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992, 339, 89-91. Calvo, C.; Ferrer, M. R.; Martinez-Checa, F.; Bejar, V.; Quesada, E. Some rheological properties of the extracellular polysaccharide produced by Volcaniella eurihalina F2-7. Appl. Biochem. Biotechnol. 1995, 55, 45-54. Cerning, J. Exocellular exopolysaccharides by lactic acid bacteria. Fems Microbiol. Rev. 1990, 87, 113-130. Cerning, J.; Bouillanne, C.; Landon, M.; Desmazeaud, M. J. Isolation and characterization of exopolysaccharides from slime-forming mesophilic lactic aicd bacteria. J. Dairy Sci. 1992, 75, 692-699. Chen, C. C.; Liu, Y. W.; Ker, Y. B.; Wu, Y. Y.; Lai, E. Y.; Chyau, C. C.; Hseu, T. H.; Peng, R. Y. Chemical characterization and anti-inflammatory effect of polysaccharides fractionated from submerge-cultured Antrodia camphorate mycelia. J. Agric. Food Chem. 2007, 55, 5007-5012. Choi, S. S.; Kim, Y.; Han, K. S.; You, S.; Oh, S.; Kim, S. H. Effects of Lactobacillus strains on cancer cell proliferation and oxidative stress in vitro. Lett. Appl. Microbiol. 2006, 42, 452-458. Cohen, J. The immunopathogenesis of sepsis. Nature 2002, 420, 885-891. Daeschel, M. A. Antimicrobial substances from lactic acid bacteria for use as food preservatives. Food Technol. 1989, 43, 164-166. Darfeuille-Michaud, A.; Neut, C.; Barnich, N.; Lederman, E.; Di Martino, P.; Desreumaux, P.; Gambiez, L.; Joly, B.; Cortot, A.; Colombel, J. F. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology 1998, 115, 1405-1413. de Vuyst, L.; Degeest, B. Heteropolysaccharides from lactic acid bacteria. Fems Microbiol. Rev. 1999, 23, 157-177. Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., Smith, F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28, 350-356. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H. O. Ulcerative colitis and colorectal canse. A population-baced study. N. Engl. J. Med. 1990, 323, 1228-1233. FAO/ WHO. 2001. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/ WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, October 1-4, 2001. Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S., Girardin, S. E. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1β generation. Clin. Exp. Immunol. 2006, 147, 227-235. Forsen, R.; Heiska, E.; Herva, E.; Avrilommi, H. Immunobiological effects of Streptococcus cremoris from cultured ‘viili’; application of human lymphocyte culture techniques. Int. J. Food Microbiol. 1987, 5, 41-47. Frazier, W.C.; Westhoff, D. C. 1998. Microorganisms important in food microbiology. In: Frazier WC, Westhoff DC, eds. Food Microbiology. 4th ed. New York: McGraw-Hill Book Co. Gilliland, S. E.; Nelson, C. R.; Maxwell, C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl. Environ. Microbiol. 1985, 49, 377-381. Glauser, M. P., Heumann, D., Le, R. D., Barras, C. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc. Natl. Acad. Sci. USA, 1994, 91, 7922-7926. Griess, P. 'Bemerkungen zu der Abhandlung der HH. Weselky und Benedikt Ueber einige Azoverbindungen'. Berichte der Deutschen chemischen Gesellschaft 1879, 12, 426-428. Grobben, G. J.; Smith, M. R.; Sikkema, J.; de Bont J. A. M. Influence of fructose and glucose on the production of exopolysaccharides and the activities of enzymes involved in the sugar metabolism and the synthesis of sugar nucleotides in Lactobacillus delbrueckii subsp. bulgaricus NCFB 2772. Appl. Microbiol. Biotechnol. 1996, 46, 279-284. Gyde, S. N.; Prior, P.; Allan, R. N.; Stevens, A.; Jewell, D. P.; Truelove, S. C.; Lofberg, R.; Brostrom, O.; Hellers, G. Colorectal cancer in ulverative colitis: a cohort study of primary referrals from three centres. Gut 1988, 29, 206-217. Handschin, C.; Spiegelman, B. M. The role of exercise and PGC1α in inflammation and chronic disease. Nature 2008, 454, 463-469. Hashimoto, S.; Nomoto, K.; Matsuzaki, T.; Yokokura, T.; Mutai, M. Oxygen radical production by peritoneal macrophages and kupffer cells elicited with Lactobacillus casei. Infec. Immun. 1984, 44, 61-67. Hatcher, G. E.; Lambrecht, R. S. Augmentation of macrophage phagocytic-activity by cell-free-extracts of selected lactic acid-producing bacteria. J. Dairy Sci. 1993, 76, 2485-2492. Heumnn, D. C.; Barras, A.; Severin, M. P.; Glauser, M.; Tomasz, A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor-alpha and interlukin-6 by human monocytes. Infec. Immun. 1994, 62, 2715-2721. Holzapfel, W. H.; Haberer, P.; Snel, J.; Schillinger, U.; Huis in’t Veld J. H. J. Overview of gut flora and probiotics. Int. J. Food Microbiol. 1998, 41, 85-101. Hooper, D. C.; Bagasra, O.; Marini, J. C.; Zborek, A.; Ohnishi, S. T.; Kean, R.; Champion, J. M.; Sarker, A. B.; Bobroski, L.; Farber, J. L.; Akaike, T.; Maeda, H.; Koprowski, H. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1997, 94, 2528-2533. J. Fernando del Rosario, M. D. Inflammatory bowel disease. 2010. Retrieved July 3, 2011, from http://kidshealth.org/PageManager.jsp?dn=KidsHealth&lic=1&ps=107&cat_id=137&article_set=22980. Kim, J. E.; Kim, J. Y.; Lee, K. W.; Lee, H. J. Cancer chemopreventive effects of lactic acid bacteria. J. Microbiol. Biotechnol. 2007, 17, 1227-1235. Kimmel, S. A.; Roberts, R. F.; Ziegler, G. R. Optimization of exopolysaccharide production by Lactobacillus delbrueckii subsp. bulgaricus RR grown in a semidefined medium. Appl. Environ. Microbiol. 1998, 64, 659-664. Kitazawa, H.; Nomura, M.; Itoh, T.; Yamaguchi, T. Functional alteration of macrophages by a slime-forming encapsulated Lactococcus lactis ssp. cremoris. J. Dairy Sci. 1991, 74, 2082-2088. Kitazawa, H.; Toba, T.; Itoh, T.; Kumano, N.; Adachi, S.; Yamaguchi, T. B-cell mitogen produced by slime-forming encapsulated Lactococcus lactis ssp. cremoris isolated from ropy sour milk, viili. J. Dairy Sci. 1993, 76, 1514-1519. Knowles, R. G. Nitric oxide synthases. Biochem. Soc. Trans. 1996, 24, 875-878. Komatsu, M.; Kobayashi, D.; Saito, K.; Furuya, D.; Yaqihashi, A.; Araake, H.; Tsuji, N.; Sakamaki, S.; Niitsu, Y.; Watanabe, N. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immune-PCR. Clin. Chem. 2001, 47, 1297-1301. Kong, J.; Lee, H.; Hong, J.; Kang, Y.; Kim, J.; Chang, M.; Bae, S. Utilization of a cell-bound polysaccharide produced by the marine bacterium Zooglea sp.: New biomaterial for metal adsorption and enzyme immobilization. J. Mar. Biotechnol. 1998, 6, 99-103. Kumar, A. S.; Mody, K.; Jha, B. Bacterial exopolysaccharides – a perception. J. Basic Microbiol. 2007, 47, 103-117. Liu, C.; Lu, J.; Lu, L.; Liu, Y.; Wang, F.; Xiao, M. Isolation, structural characterization and immunological activity of an exopolysaccharide produced by Bacillus licheniformis 8-37-0-1. Bioresour, Technol. 2010, 101, 5528-5533. Looijesteijn, P. J.; van Casteren, W. H. M.; Tuinier, R.; Dosewijk-Vorage, C. H. L.; Hugenholtz, J. Influence of different substrate limitations on the yield, composition and molecular mass of exopolysaccharides produced by Lactococcus lactis subsp. cremoris in continuous cultures. J. Appl. Microbiol. 2000, 89, 116-122. Luderitz, O.; Freudenberg, M. A.; Galanos, C.; Lehmann, V.; Rietsche, E. T.; Shaw, D. H. Lipopoysaccharides of gram-negative bacteria. Curr. Top. Membr. Transport 1982; 17, 79-151. Macura, D.; Townsley, P. M. Scandinavian ropy milk-identification and characterization of endogenous ropy lactic streptococci and their extracellular excretion. J. Dairy Sci. 1984, 67, 735-744. Menezes, J.; Hierholzer, C.; Watikins, S. S.; Lyons, V.; Peitzman, A. B.; Billiar, T. R.; Tweardy, D. J.; Harbrecht, B. G. A novel nitric oxide scavenger decreases liver injury and improves survival after hemorrhagic shock. Am. J. Physiol. 1999, 277, G144-G151. Miyake, K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 2004, 12, 186-192. Morgan, L.; Dabco, D. C. Nitric oxide: a challenge to chiropractic. J. Can. Chiropr. Assoc. 2000, 44, 40-48. Morrissette, N.; Gold, E.; Aderem, A. The macrophage – a cell for all seasons. Trends Cell Biol. 1999, 9, 199-201. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63. Mozzi, F.; Savoy de Giori, G.; Oliver, G.; Font de Valdez, G. Exopolysaccharide production by Lactobacillus casei.Ⅱ. Influence of the carbon source. Milchwissenschaft 1995, 50, 307-309. Nakajima, H.; Suzuki, Y.; Kaizu, H.; Hirota, T. Cholesterol-lowering activity of ropy fermented milk, J. Food Sci. 1992, 57, 1327-1329. Netea, M. G.; van Deuren, M.; Kullberg, B. J.; Cavaillon, J.. M.; Van der Meer, J. W. Dose the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 2002, 23, 135-139. Oda, M.; Hasegawa, H.; Komatsu, S.; Kambe, M.; Tsuchiya, F. Anti-tumor polysaccharide from Lactobacillus sp. Agric. Biol. Chem. 1983, 47, 1623-1625. Ohkuma, S.L Katsura, M. Nitric oxide and peroxynitrite as factors to stimulate neurotransmitter release in the CNS. Prog. Neurobiol. 2001, 64, 97-108. Okutani, K. Antitumor and immunostimulant activities of polysaccharides produced by a marine bacterium of the genus Vibrio. Bull. Soc. Sci. Fish. 1984, 50, 1035-1037. Okutani, K. Antiviral activities of sulfated derivatives of a fucosamine-containing polysaccharide of marine bacterial origin. Nippon Suisan Gakkaishi 1992, 58, 927-930. Park, S. Y.; Cho, J. H.; Ma, W.; Choi, H, J.; Han, J. S. Phospholipase D2 acts as an important regulator in LPS-induced nitric oxide synthesis in Raw 264.7 cells. Cell. Signal. 2010, 22, 619-628. Peňa, J. A.; Rogers, A. B.; Ge, Z.; Ng, V.; Li, S. Y.; Fox, J. G.; Versalovic, J. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect. Immun. 2005, 73, 912-920. Peňa, J. A.; Versalovic, J. Lactobacillus rhamnosus GG decreases TNF-α production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 2003, 5, 277-285. Ralston, S. H. The Michael mason prize essay 1997. Nitric oxide and bone: what a gas! Br. J. Rheumatol. 1997, 36, 831-838. Ransohoff, D. F. Colon cancer in ulcerative colitis. Gastroenterology 1988, 94, 1089-1091. Reddy, G.; Altaf, M.; Naveena, B. J.; Venkateshwar, M.; Kumar, E. V. Amylolytic bacterial lactic acid fermentation — A review. Biotechnol. Adv. 2008, 26, 22-34. Ricciardi, A.; Clementi, F. Exopolysaccharides from lactic acid bacteria: structure, production and technological applications. Ital. J. Food Sci. 2000, 12, 23-45. Rietschel, E. T., Brade, L., Lindner, B., Zahringer, U. Molecular biochemistry of lipopolysaccharides. In Bacterial Endotoxic Lipopolysaccharides. Morrison, D. C. J., Ryan, L., Eds.; CRC Press: Boca Raton, FL. 1992; 3-42. Ruas-Madiedo, P.; de los Reyes-Gavilan, C. G. Invited review: methods for the screening, isolation, and characterization of exopolysaccharides produced by lactic acid bacteria. J. Dairy Sci. 2005, 88, 843-856. Ruas-Madiedo, P.; Hugenholtz, J.; Zoon, P. An overview of the functionality of exopolysaccharides produced by lactic acid bacteria. Int. Dairy J. 2002, 12, 163-171. Rutgeerts, P.; Goboes, K.; Peeters, M.; Hiele, M.; Penninckx, F.; Aerts, R.; Kerremans, R.; Vantrappen, G. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991, 338, 771-774. Sokol, H.; Antand-Pigneur, B.; Watterlot, L.; Lakhdari, O.; Blottiere, H. M.; Grangette, C.; Trugnan, G.; Dore, J. M.; Thomas, G.; Marteau, P. R.; Seksik, P.; Langella, P. Gastroenterology 2008, 134, A359-A359. Sokol, H.; Seksik, P.; Rigottier-Gois, L.; Lay, C.; Lepage, P.; Podglajen, I.; Marteau, P.; Dore, J. Specificties of the fecal microbiota in inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12, 106-111. Sreejayan; Rao, M. N. A. Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol. 1997, 49, 105-107. Stuehr, D. J.; Marletta, M. A. Mammalian nitrate biosynthesie: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. USA 1985, 82, 7738-7742. Tamir, S.; Tannenbaum, S. R. The role of nitric oxide (NO.) in the carcinogenic process. Biochim. Biophys. Acta 1996, 1288, F31-F36. Tannock, G. W. Probiotic properties of lactic acid bacteria: Plenty of scope for fundamental R and D. Trends Biotechnol. 1997, 15, 270-274. Tresca, A. J. Colon cancer and IBD- are you at risk? In About.com Health's Disease and Condition, 2010 (April 10), Retrieved July 3, 2011, from the World Wide Web: http://ibdcrohns.about.com/cs/colorecalcancer/a/ibdcolonrisk.htm. Tsai, P. J.; Tsai, T. H.; Yu, C. H.; Ho, S. C. Evaluation of NO-suppressing activity of several Mediterranean culinary spices. Food Chem. Toxicol. 2007, 45, 440-447. van Geel-Schuttern, G. H., Flesch, F., ten Brink, B., Smith, M. R., Dijkhuizen, L. Screening and characterization of Lactobacillus strains producing large amounts of exopolysaccharides. Appl. Microbiol. Biotechnol. 1998, 50, 697-703. van Kranenburg, R.; van Swam, II; Marugg, J. D.; Kleerebezem, M.; de Vos, W. M. Exopolysaccharide biosynthesis in Lactococcus lactis NIZO B40: functional analysis of the glycosyltransferase genes involved in synthesis of the polysaccharide backbone. J. Bacteriol. 1999, 181, 338-340. Vinderola, G.; Perdigon, G.; Duarte, J.; Farnworth, E.; Matar, C. Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine 2006, 36, 254-260. Wu, M. H.; Pan, T. M.; Wu, Y. J.; Chang, S. J.; Chang, M. S.; Hu, C. Y. Exopolysaccharide activities from probiotic bifidobacterium: immunomodulatory effects (on J774A.1 macrophages) and antimicrobial properties. Int. J. Food Microbiol. 2010, 144, 104-110. Yermilov, V.; Rubio, J.; Becchi, M.; Friesen, M. D.; Pignatelli, B.; Ohshima, H. Formation of 8-nitroguanine by the reaction of guanine with peroxynitrite in vitro. Carcinogenesis 1995, 16, 2045-2050. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24053 | - |
dc.description.abstract | 發炎性腸道疾病 (Inflammatory bowel disease, IBD) 為一種慢性發炎疾病,長期罹患 IBD 之患者其罹患結腸癌之風險會增加,而益生菌和益生質對於 IBD 治療很有發展潛力。乳酸菌為腸道中之益生菌,對宿主健康有很大益處,而其部分原因可能與其所產之胞外多醣 (Exopolysaccharides, EPS) 的生理活性有關。本研究以具有對雙叉桿菌生長助生性之乳酸桿菌 (Lactobacillus acidophilus BCRC 14079、L. casei 01、L. delbrueckii subsp. bulgaricus BCRC 10696、L. plantarum BCRC 11697 及 L. rhamnosus GG BCRC 16000) 胞外多醣為材料,並利用脂多醣 (Lipopolysaccharide, LPS) 誘導小鼠巨噬細胞株 (RAW 264.7 cell line) 之三種發炎模式 (預防發炎模式、修復發炎模式及 EPS 與 LPS 共培養發炎模式) 進行,探討乳酸桿菌之胞外多醣其抗發炎作用。實驗結果顯示,乳酸桿菌胞外多醣在 EPS與 LPS 共培養發炎模式下,具有較佳之抗發炎效果,而五種乳酸桿菌胞外多醣皆具有清除 NO (Nitric oxide) 之能力,亦可抑制 NO 生成及 TNF-α 產生,且其效果具有濃度效應 (Dose-dependent),其中以 L. plantarum BCRC 11697 產生之胞外多醣其抑制 NO 生成的效果最佳,故乳酸桿菌胞外多醣具有抗發炎之作用,有發展減緩因發炎而造成疾病之潛力。在抑制結腸癌細胞增生實驗中,五種乳酸桿菌胞外多醣作用 HT-29 細胞 48 小時皆有抑制增生之作用;另一方面,除了 L. delbrueckii subsp. bulgaricus BCRC 10696 的胞外多醣之外,其餘四種乳酸桿菌胞外多醣皆有抑制 Caco-2 細胞增生之作用,且隨著作用時間增加,其抑制增生效果越好。因此,乳酸桿菌之胞外多醣不但具有抗發炎作用亦可抑制結腸癌細胞增生之作用,具有發展治療 IBD 之潛力。 | zh_TW |
dc.description.abstract | Inflammatory bowel disease (IBD) was a chronic inflammatory disease, and long-time suffered from IBD could increase risk of colon cancer. Several lactic acid bacteria (LAB) were probiotics, the beneficical effects on human health of LAB could be attributable to positive physiological effect of exopolysaccharide (EPS). Study had shown that probiotics and prebiotics were showing increasing promise as treatments for IBD. We employed EPS produced by five Lactobacillus spp. (Lactobacillus acidophilus BCRC 14079、L. casei 01、L. delbrueckii subsp. bulgaricus BCRC 10696、L. plantarum BCRC 11697 and L. rhamnosus GG BCRC 16000), which had positive prebiotic effect on the growth of Bifidobacterium, as materials and three lipopolysaccharide (LPS)-induce inflammation models (preventive inflammation model, repairing inflammation model, and co-treated inflammation model) were established with murine macrophages (RAW 264.7 cell line) to evaluate the anti-inflammatory activity of EPS. Results revealed that all of EPS produced by Lactobacillus spp. had better anti-inflammatory activity in EPS and LPS co-treated inflammation model. All of EPS had NO scavenging activity, and could inhibit the production of TNF-α and nitric oxide (NO) in a dose-dependent manner. Especially, EPS of L. plantarum BCRC 11697 have the lowest IC50 (188.4 ± 3.0 μg/ml), shown that had the best inhibition of NO production. So, all of EPS had anti-inflammatory activity. Furthermore, all of EPS had anti-proliferation on HT-29 cell after 48 h incubation. Also, besides the EPS from L. delbrueckii subsp. bulgaricus BCRC 10696, four of EPS of Lactobasillus spp. could inhibit the proliferation of Caco-2 cells in a time-dependent manner. Conclusively, all of EPS produced by Lactobacillus spp. had anti-inflammatory activity and anti-proliferative activity of colon cancer cell line, so EPS had potential to develop treatment of IBD. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:14:55Z (GMT). No. of bitstreams: 1 ntu-100-R98641016-1.pdf: 1491441 bytes, checksum: fbf3ff2c428779119ea34db5576ea9b2 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 謝誌 I
中文摘要 III Abstract IV 目錄 VI 圖目錄 X 表目錄 XII 壹、前言 1 貳、文獻整理 2 一、乳酸菌 2 (一) 乳酸菌之特性 2 (二) 乳酸菌之分類 3 二、胞外多醣 9 三、乳酸菌胞外多醣 12 (一) 乳酸菌胞外多醣之分子大小與組成 12 (二) 乳酸菌胞外多醣之生產 14 (三) 乳酸菌胞外多醣之功效 16 四、發炎反應與巨噬細胞 19 (一) 發炎反應 (Inflammation) 19 (二) 巨噬細胞 (Macrophage) 21 (三) 脂多醣 (Lipopolysaccharide, LPS) 21 (四) LPS 誘導巨噬細胞產生發炎反應 21 (五) 一氧化氮 (NO) 26 五、發炎性腸道疾病 27 參、材料與方法 29 一、實驗架構 29 二、實驗材料 31 (一) 試驗菌株 31 (二) 試驗細胞株 31 (三) 培養基 31 (四) 化學藥品 32 (五) 儀器設備 33 (六) 酵素連結免疫吸附分析之抗體套組 35 三、實驗方法 36 (一) 菌粉活化與保存 36 (二) 菌種活化 36 (三) 細胞株的活化、繼代培養與保存 37 (四) 製備胞外多醣 38 (五) 總固形物含量 39 (六) 胞外多醣含量測定 (酚-硫酸法) 39 (七) 細胞存活率測定 (MTT assay) 40 (八) RAW264.7 小鼠巨噬細胞發炎模式 41 (九) NO 含量測定 (Griess assay) 41 (十) 清除 NO 能力測定 42 (十一) 細胞激素含量測定 (TNF-α ELISA kit) 42 (十二) 統計分析 44 肆、結果與討論 45 一、乳酸桿菌胞外多醣產量 45 二、乳酸桿菌胞外多醣對 RAW 264.7 之細胞毒性 47 三、乳酸桿菌胞外多醣於三種發炎模式下其 NO 含量之影響 50 (一) L. acidophilus BCRC 14079 之胞外多醣於三種發炎模式下 NO 生成之影響 50 (二) L. casei 01 之胞外多醣於三種發炎模式下 NO 生成之影響 52 (三) L. delbrueckii subsp. bulgaricus BCRC 10696 之胞外多醣於三種發炎模式下 NO 生成之影響 52 (四) L. plantarum BCRC 11697 之胞外多醣於三種發炎模式下 NO 生成之影響 55 (五) L. rhamnosus GG BCRC 16000 之胞外多醣於三種發炎模式下 NO 生成之影響 55 四、比較五種乳酸桿菌胞外多醣對 LPS 誘導 RAW 264.7 細胞株發炎其 NO 生成之影響 59 五、比較五種乳酸桿菌胞外多醣對 LPS 誘導 RAW 264.7 細胞株發炎其 TNF-α 含量之影響 62 六、比較五種乳酸桿菌胞外多醣清除 NO 之能力 64 七、比較五種乳酸桿菌胞外多醣抑制 HT-29 細胞株之效果 66 八、比較五種乳酸桿菌胞外多醣抑制 Caco-2 細胞株之效果 69 伍、結論 72 參考文獻 73 附錄 85 附表一、L. acidophilus BCRC 14079之胞外多醣於三種發炎模式下 NO 生成之影響 85 附表二、L. casei 01之胞外多醣於三種發炎模式下 NO 生成之影響 86 附表三、L. delbrueckii subsp. bulgaricus BCRC 10696 之胞外多醣於三種發炎模式下 NO 生成之影響 87 附表四、L. plantarum BCRC 11697 之胞外多醣於三種發炎模式下 NO 生成之影響 88 附表五、L. rhamnosus GG BCRC 16000 之胞外多醣於三種發炎模式下 NO 生成之影響 89 | |
dc.language.iso | zh-TW | |
dc.title | 數株乳酸桿菌胞外多醣之抗發炎作用及抑制結腸癌細胞增生之研究 | zh_TW |
dc.title | Effects of Exopolysaccharides Produced by Several Lactobacillus spp. on the Anti-inflammatory Activity and Antiproliferation of Colon Cancer Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 丘志威,蔡國珍,潘崇良,顏聰榮,周正俊 | |
dc.subject.keyword | 發炎性腸道疾病 (IBD),胞外多醣,抗發炎,RAW 264.7, | zh_TW |
dc.subject.keyword | inflammatory bowel disease (IBD),exopolysaccharides (EPS),anti-inflammatory activity,RAW 264.7 cell line, | en |
dc.relation.page | 89 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-08-01 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 食品科技研究所 | zh_TW |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.46 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。